Cargando…
Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder
Adherence is a major factor in the effectiveness of the injectable extended-release naltrexone as a relapse prevention treatment in opioid use disorder. We examined the value of a variant of the Go/No-go paradigm in predicting extended-release naltrexone adherence in 27 detoxified opioid use disorde...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403086/ https://www.ncbi.nlm.nih.gov/pubmed/30690502 http://dx.doi.org/10.1093/ijnp/pyz002 |
_version_ | 1783400506064896000 |
---|---|
author | Shi, Zhenhao Jagannathan, Kanchana Wang, An-Li Fairchild, Victoria P Lynch, Kevin G Suh, Jesse J Childress, Anna Rose Langleben, Daniel D |
author_facet | Shi, Zhenhao Jagannathan, Kanchana Wang, An-Li Fairchild, Victoria P Lynch, Kevin G Suh, Jesse J Childress, Anna Rose Langleben, Daniel D |
author_sort | Shi, Zhenhao |
collection | PubMed |
description | Adherence is a major factor in the effectiveness of the injectable extended-release naltrexone as a relapse prevention treatment in opioid use disorder. We examined the value of a variant of the Go/No-go paradigm in predicting extended-release naltrexone adherence in 27 detoxified opioid use disorder patients who were offered up to 3 monthly extended-release naltrexone injections. Before extended-release naltrexone, participants performed a Go/No-go task that comprised positively valenced Go trials and negatively valenced No-go trials during a functional magnetic resonance imaging scan. Errors of commission and neural responses to the No-go vs Go trials were independent variables. Adherence, operationalized as the completion of all 3 extended-release naltrexone injections, was the outcome variable. Fewer errors of commission and greater left accumbal response during the No-go vs Go trials predicted better adherence. These findings support the clinical potential of the behavioral and neurophysiological correlates of response inhibition in the prediction of extended-release naltrexone treatment outcomes in opioid use disorder. |
format | Online Article Text |
id | pubmed-6403086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64030862019-03-12 Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder Shi, Zhenhao Jagannathan, Kanchana Wang, An-Li Fairchild, Victoria P Lynch, Kevin G Suh, Jesse J Childress, Anna Rose Langleben, Daniel D Int J Neuropsychopharmacol Brief Report Adherence is a major factor in the effectiveness of the injectable extended-release naltrexone as a relapse prevention treatment in opioid use disorder. We examined the value of a variant of the Go/No-go paradigm in predicting extended-release naltrexone adherence in 27 detoxified opioid use disorder patients who were offered up to 3 monthly extended-release naltrexone injections. Before extended-release naltrexone, participants performed a Go/No-go task that comprised positively valenced Go trials and negatively valenced No-go trials during a functional magnetic resonance imaging scan. Errors of commission and neural responses to the No-go vs Go trials were independent variables. Adherence, operationalized as the completion of all 3 extended-release naltrexone injections, was the outcome variable. Fewer errors of commission and greater left accumbal response during the No-go vs Go trials predicted better adherence. These findings support the clinical potential of the behavioral and neurophysiological correlates of response inhibition in the prediction of extended-release naltrexone treatment outcomes in opioid use disorder. Oxford University Press 2019-01-23 /pmc/articles/PMC6403086/ /pubmed/30690502 http://dx.doi.org/10.1093/ijnp/pyz002 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of CINP. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Brief Report Shi, Zhenhao Jagannathan, Kanchana Wang, An-Li Fairchild, Victoria P Lynch, Kevin G Suh, Jesse J Childress, Anna Rose Langleben, Daniel D Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder |
title | Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder |
title_full | Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder |
title_fullStr | Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder |
title_full_unstemmed | Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder |
title_short | Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder |
title_sort | behavioral and accumbal responses during an affective go/no-go task predict adherence to injectable naltrexone treatment in opioid use disorder |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403086/ https://www.ncbi.nlm.nih.gov/pubmed/30690502 http://dx.doi.org/10.1093/ijnp/pyz002 |
work_keys_str_mv | AT shizhenhao behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder AT jagannathankanchana behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder AT wanganli behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder AT fairchildvictoriap behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder AT lynchkeving behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder AT suhjessej behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder AT childressannarose behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder AT langlebendanield behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder |